Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation

Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation

Abstract: the acute disturbances of cerebral circulation incidence accounts for nearly 70-80% of all such diseases in population, while this annual rate in Russian health care is about 2,19 cases on 1000 individuals. Pharmacoeconomic evaluation of this pathology contributes to the improvement of app...

Full description

Bibliographic Details
Main Authors:	A. Yu. Kulikov, L. A. Komarov
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2015-03-01
Series:	Фармакоэкономика
Subjects:	pharmacoeconomic analysis the acute disturbances of cerebral circulation сerebrolysin standard therapy cost-effectiveness analysis budget impact analysis health technology assessment cost analysis.
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/49

Similar Items

Pharmacoeconomic analysis in various nosologies
by: A. A. Svistunov, et al.
Published: (2022-12-01)

Сerebrolysin® influences in Sod- and sws-dependent neurodegenerative models of Drosophila melanogaster
by: Nataliya Matiytsiv, et al.
Published: (2023-06-01)

Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis
by: R. I. Yagudina, et al.
Published: (2015-03-01)

PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH CARBONIC ANHYDRASE INHIBITORS
by: A. Yu. Kulikov, et al.
Published: (2015-03-01)

Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review
by: Hui-Yao Huang, et al.
Published: (2020-11-01)

PHARMACOECONOMIC ANALYSIS OF CHRONIC HEART FAILURE DRUG THERAPY IN PATIENTS WITH COMORBID CONDITIONS
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS
by: M. Yu. Frolov, et al.
Published: (2017-05-01)

Pharmacoeconomic Evaluations of Oral Anticancer Drugs
by: Nazish Matti, et al.
Published: (2023-08-01)

COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS
by: M. B. Kubaeva, et al.
Published: (2017-08-01)

Pharmacoeconomics of spastic cerebral palsy
by: R. I. Yagudina, et al.
Published: (2018-02-01)

Pharmacoeconomics of Bronchial Asthma
by: Ivanova Zlatina I., et al.
Published: (2019-06-01)

PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER
by: R. I. Yagudina, et al.
Published: (2015-03-01)

PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH COMBINATIONS OF PROSTAGLANDIN ANALOGUES AND BETA-BLOCKERS
by: A. Yu. Kulikov, et al.
Published: (2015-03-01)

Pharmacoeconomic analysis of cost-benefit in evaluating the effectiveness of treatment for epilepsy in adults
by: P. N. Vlasov, et al.
Published: (2010-06-01)

PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
by: N. A. Avksentyev, et al.
Published: (2018-08-01)

PHARMACOECONOMIC STUDY OF PRIMARY OPEN-ANGLE GLAUCOMA TREATMENT WITH FIX COMBINATION OF CARBONIC ANHYDRASE INHIBITORS AND BETABLOCKERS
by: M. V. Protsenko
Published: (2015-03-01)

RETRACTED: Opportunities of the method «Budget impact analysis» for performing pharmacoeconomic research
by: V. V. Ryazhenov, et al.
Published: (2022-06-01)

Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus
by: A. G. Tolkushin, et al.
Published: (2018-11-01)

COST OF ILLNESS ANALYSIS: TYPES, METHODOLOGY, RUSSIAN SPECIFICS
by: R. I. Yagudina, et al.
Published: (2015-03-01)

Pharmacoeconomic analysis of the use of actovegin in patients with post-stroke cognitive impairment in the health care system of the Russian Federation
by: V. V. Ryazhenov, et al.
Published: (2018-11-01)

Pharmacoeconomics of chronic kidney disease
by: R. I. Yagudina, et al.
Published: (2018-02-01)

REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS
by: Andrey Vladislavovich Pavlysh, et al.
Published: (2015-09-01)

Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer
by: N. A. Avxentyev, et al.
Published: (2020-02-01)

PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
by: A. U. Kulikov, et al.
Published: (2015-03-01)

Pharmacoeconomic analysis of dapagliflozin in patients with chronic kidney disease and type 2 diabetes in the Russian Federation
by: Sergey V. Nedogoda, et al.
Published: (2024-02-01)

Pharmacoeconomic analysis of Anti-inhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia
by: R. I. Yagudina, et al.
Published: (2015-03-01)

CLINICAL EFFICIENCY AND THE PHARMACOECONOMIC ANALYSIS OF ALLERGEN IMMUNOTHERAPY AT PATIENTS WITH MILD AND MODERATE ALLERGIC BRONCHIAL ASTHMA
by: Elena Albertovna Sobko, et al.
Published: (2015-09-01)

PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2016-04-01)

Pharmacoeconomic evaluation of aspirin therapy in pharmaceutical prevention of the first acute myocardial infarction in patients with stable angina
by: A. Yu. Kulikov, et al.
Published: (2010-02-01)

PHARMACOECONOMIC ANALYSIS OF OLMESARTAN THERAPY IN THE INDIVIDUAL–LEVEL MANAGEMENT OF ARTERIAL HYPERTENSION
by: S. G. Gorokhova, et al.
Published: (2012-08-01)

Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation
by: S. V. Nedogoda, et al.
Published: (2020-08-01)

Pharmacoeconomics of three therapeutic schemes for anti-tuberculosis therapy induced liver injury in China
by: Chen Yu, et al.
Published: (2018-03-01)

Retrospective pharmacoeconomic study of antibiotic therapy in community-acquired pneumonia
by: A. A. Taube, et al.
Published: (2023-11-01)

Pharmacoeconomic analysis of naftidrofuryl for treatment of ischemic stroke
by: A. E. Cheberda, et al.
Published: (2018-05-01)

PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2018-02-01)

Use of fendivia transdermal therapeutic system in Russian patients with malignant neoplasms during palliative care: Pharmacoeconomic aspects
by: V V Riazhenov, et al.
Published: (2014-02-01)

THE FEATURES OF METHODOLOGY FOR PHARMACOECONOMICS ANALYSIS OF VACCINATION
by: A. Yu. Kulikov, et al.
Published: (2015-03-01)

Pharmacoeconomic analysis of blood glucose meter Contour TS in diabetes treatment
by: A. U. Kulikov, et al.
Published: (2015-03-01)

Pharmacoeconomic particulars of ovaries cancer’s treatment
by: V N Zhurman, et al.
Published: (2015-06-01)

Outlook of Pharmacoeconomics and its status in Nepal
by: Sabita Paudel
Published: (2018-03-01)